Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report). The associated price target remains the same with $45.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on the promising potential of Abivax’s obefazimod in treating moderate-to-severely active ulcerative colitis. The upcoming Phase 3 ABTECT program results, expected in Q3 2025, are anticipated to be a significant catalyst for the stock, given the drug’s novel mechanism and oral delivery. The drug’s ability to address unmet needs in late-line refractory patients, coupled with its strong safety profile, further supports the positive outlook.
Additionally, the Phase 2 maintenance data have shown exceptional results, and if the Phase 3 induction data are positive, it would validate the earlier findings and enhance the prospects for the maintenance data. The potential for a New Drug Application submission in H2 2026, contingent on successful Phase 3 outcomes, adds to the investment appeal. Overall, the low current valuation of ABVX compared to historical IBD peers presents a compelling opportunity for investors.
According to TipRanks, Slutsky is an analyst with an average return of -6.2% and a 33.71% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Enliven Therapeutics, and Olema Pharmaceuticals.